Differentiated approach to the use of optimal medical therapy in patients with various clinical forms of stable ischemic heart disease

A total of 137 male patients with stable ischemic heart disease (SIHD), average age 62.3 ± 7.46 years, were divided into 3 groups depending on the initial measurements of blood pressure (BP) and heart rate (HR). Group 1 included patients with elevated blood pressure and/or heart rate (44.5% of patients); Group 2 included patients with normal blood pressure and/or heart rate (38.7%); Group 3 included patients with lowered blood pressure and/or heart rate (16.8%). Patients of Group 1 received beta-adrenergic blockers (BABs) or non-dihydropyridine calcium channel blockers (NDCCBs), in some cases ivabradine-containing BABs (Raenom®, Gedeon Richter) at doses required to achieve target blood pressure and heart rate. The patients of Group 2 received a limited range of drugs above listed due to their blood pressure and heart rate measurements, and the patients of Group 3 did not receive any due to the low levels of such measurements. Effectiveness of the therapy in patients of Group I was the highest. The use of trimetazidine MB (Predizin MB®, Gedeon Richter) has significantly improved the results of treatment in patients of Groups 2 and 3. Trimetazidine MB added to the therapy in patients of Group 1 improved the effectiveness of treatment. Prolongation of trimetazidine MB therapy contributed to improvement of its anti-ischemic effect. Thus, BABs, NDCCBs and ivabradine entered into the foreground, as an optimal medical therapy (OMT) in patients with elevated blood pressure and heart rate measurements. Trimetazidine MB, and ivabradine in some cases prevail in patients with normal and low blood pressure and/or heart rate. It should be stated that patients with various hemodynamic variants of SIHDa require a differentiated approach to the choice of OMT.

1. Boden W.E., O’ Rourke R.A., Teo K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356: 1503-16.

2. Shalnova S.A., Oganov R.G., Stag F.G., Ford I. On behalf of the participants of CLARIFY Registry. Ischemic heart disease. Modern reality according to the global CLARIFY Registry. Kardiologia. 2013; 8: 28-33. (In Russ).

3. Fihn S.D., Gardin J.M., Abrams J., et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCA/STS guideline for diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012; 60: 44-164.

4. 2013 ESC Guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 34: 2949-3003.

5. NICE. Stable angina: management. NICE Clinical Guidelines CG126. London: National Institute for the Health and Care Excellence, 2016.

6. Shaposhnik I.I. Too many guidelines and one patient. RMJ 2014; 12: 923-927. (In Russ).

7. Cardiovascular prophylaxis, 2017. Russian national guidelines. Rossiysky Kardiologichesky Zhurnal. 2018; 23 (6): 7-122. (In Russ).

8. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018; 39(33): 1-98.

9. Povetkin S.V., Luneva Yu.V. Study of the clinical efficacy of original and generic ivabradine in patients with stable exertional angina (comparative study). Ratsionalnaya Farmakoterapia v Kardiologii. 2018; 14 (1): 34-39. (In Russ).

10. Aronov D.M. Consensus of experts on the role and place of the myocardial cytoprotector trimetazidine in the treatment of patients with chronic forms of ischemic heart disease. Serdtse. 2015; 14 (4): 256-260 (In Russ).

11. Zakharova O.V. Trimetazidine therapy for microvascular angina. Proceedings of the National Congress of Cardiologists. Yekaterinburg, 2016: 287288. (In Russ).

12. Koester R., Kaehler J., Ebelt H. Ivabradine in combination with beta-blocker therapy for the treatment of the stable angina pectoris in every day clinical practice. Clin Res Cardiol. 2010; 99: 665-72.